BioLife Solutions (BLFS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BLFS · Stock Price

USD 23.12-0.17 (-0.73%)

Market Cap: $1.1B

Historical price data

Market Cap: $1.1BPatents: 16Founded: 1987HQ: Bothell, United States

Sector Ranking#29 in Cell & Gene Therapy

Overview

BioLife Solutions is a publicly traded enabler of the cell and gene therapy revolution, providing mission-critical biopreservation media, cell culture optimization products, and closed-system manufacturing tools. Its strategic 'Mastering Biopreservation' platform is embedded in over 700 customer clinical applications, providing a capital-efficient, recurring revenue model insulated from direct therapeutic development risk. The company's success is tied to the broader CGT sector's growth, positioning it as a foundational supply chain partner for developers navigating the complex path from R&D to commercialization.

Cell TherapyGene TherapyRegenerative Medicine

Technology Platform

An integrated 'Mastering Biopreservation' platform comprising three pillars: 1) Biopreservation & Freeze Media (e.g., CryoStor), 2) Closed-system, automation-ready tools for cell processing, and 3) Cell culture optimization products (e.g., human platelet lysates).

Funding History

4

Total raised:$64.7M

PIPE$50MUndisclosedSep 30, 2020

IPO$8.5MUndisclosedDec 15, 2005

Series A$5MUndisclosedJun 15, 2002

Seed$1.2MUndisclosedJun 15, 1999

Opportunities

The company is poised to benefit from the rapid growth of the cell and gene therapy sector, with each new therapy approval and manufacturing scale-up driving recurring demand for its consumables and tools.

The industry trend towards closed, automated manufacturing and outsourcing to CDMOs aligns perfectly with BioLife's product strategy, expanding its total addressable market.

Risk Factors

BioLife faces significant sector concentration risk, as its success is directly tied to the funding environment and clinical progress of the broader CGT industry.

It also faces competition from larger life science tools companies and risks related to potential technological disruption in biopreservation or cell culture science.

Competitive Landscape

BioLife competes in fragmented segments against niche chemical suppliers, specialized biotech firms, and large capital equipment players. Its primary advantage is an integrated, specialized platform focused exclusively on CGT workflows, combining scientifically validated formulations, GMP-ready materials, and deep regulatory support to create significant customer stickiness.